JPRN-UMIN000002141已完成1 期
Phase I study of Multiple-Vaccine Therapy in Patient with Refractory Non-Small-Cell Lung Cancer to Chemotherapy. - Phase I study of Multiple-Vaccine Therapy in Patient with Refractory Non-Small-Cell Lung Cancer to Chemotherapy.
Department of Respiratory Medicine, Juntendo University School of Medicine0 个研究点目标入组 9 人开始时间: 2009年7月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Pregnancy 2.Breastfeeding 3.Concurrent treatment with steroids or immunosuppressing agent 4.No other malignancy requiring treatment 5.No curative traumatic wound 6.Decision of unsuitableness by principal investigator or physician-in-charge
研究者
相似试验
招募中
1 期
Phase I study of Multiple-Vaccine Therapy in Patient with Refractory Breast Cancer to Chemotherapy.Breast CancerJPRN-UMIN000002408Department of Breast and Endocrine Surgery, Juntendo University School of Medicine6
进行中（未招募）
不适用
Phase I/II trial of vaccine therapy in patients with recurrent ovarian cancer.Relapsed and platinum resistant epithelial ovarian carcinoma patients that have received one line of non-platinum chemotherapy in resistance disease setting.EUCTR2010-020233-56-NOOslo University Hospital20
招募中
2 期
Therapeutic vaccination: Phase I / II clinical study on patients randomized blinded to the experimental vaccine or placebo regimen. we want to evaluate the safety and the immunogenicity of a vaccine that includes a first administration of the
ChAdOx1.tHIVconsvX product and a second one with MVA.tHIVconsvX in HIV-1 positive adults treated early and able to control the infection for a long time.2024-514581-39-00Ospedale San Raffaele S.r.l., Ospedale San Raffaele S.r.l.33
进行中（未招募）
不适用
Phase I/II study of immunization with multiple peptides mixed with the immunological adjuvant CpG 7909 in HLA-A2 patients with metastatic melanoma LUD 03-007 - LUD 03-007HLA-A2 patients with metastatic melanomaEUCTR2004-004686-15-DEudwig Institute For Cancer Research14
进行中（未招募）
不适用
Phase I/II trial of vaccine therapy in curative resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and surviving.Prostatic cancer patients who have received curative surgery.EUCTR2010-018770-20-NOOslo University Hospital30